IL245062B - 1-(5-tert-butyl-2-aryl-pyrazol-3-yl)-3-[2-fluoro-4-[(3-oxo-4h-pyrido[2, 3-b]pyrazin-8-yl)oxy]phenyl]urea derivatives as raf inhibitors for the treatment of cancer

36 members in 19 offices

This recordMember, by publication datePriority claim9 more offices are in the list below

Priority claims
Document	Office	Kind	Date
201320729	United Kingdom	A	2013-11-25
201320729	United Kingdom	A	2013-11-25
2014053490	United Kingdom	W	2014-11-25
2014053490	United Kingdom	W	2014-11-25
13207295	–	–	–
GB20130020729	–	–	–
PCTGB2014053490	–	–	–
WO2014GB53490	–	–	–

Family members, oldest first
Document	Office	Kind
GB201320729D0	United Kingdom	D0	2014-01-08
CA2928009A1	Canada	A1	2015-05-28
WO2015075483A1	World Intellectual Property Organization (WIPO)	A1	2015-05-28
AU2014351571A1	Australia	A1	2016-05-19
IL245062A0	Israel	A0	2016-06-30
IL245062D0	Israel	D0	2016-06-30
KR20160079792A	Republic of Korea	A	2016-07-06
CN105793260A	China	A	2016-07-20
EA201690531A1	Eurasian Patent Organization (EAPO)	A1	2016-08-31
EP3074396A1	European Patent Office (EPO)	A1	2016-10-05
JP2016538345A	Japan	A	2016-12-08
US2016355510A1	United States of America	A1	2016-12-08
MX2016006119A	Mexico	A	2016-12-14
SA516371189A	Saudi Arabia	A	2017-05-05
US9725447B2	United States of America	B2	2017-08-08
US2017298066A1	United States of America	A1	2017-10-19
CN105793260B	China	B	2018-04-10
SA516371189B1	Saudi Arabia	B1	2018-06-30
SA5981B1	Saudi Arabia	B1	2018-06-30
JP6389529B2	Japan	B2	2018-09-12
US10167282B2	United States of America	B2	2019-01-01
AU2014351571B2	Australia	B2	2019-02-14
EP3074396B1	European Patent Office (EPO)	B1	2019-05-01
DK3074396T3	Denmark	T3	2019-07-29
PT3074396T	Portugal	T	2019-08-06
IL245062A	Israel	A	2019-09-26
IL245062BThis record	Israel	B	2019-09-26
PL3074396T3	Poland	T3	2019-11-29
EA034216B1	Eurasian Patent Organization (EAPO)	B1	2020-01-17
HUE045596T2	Hungary	T2	2020-01-28
ES2740325T3	Spain	T3	2020-02-05
MX372942B	Mexico	B	2020-04-03
BR112016011078A8	Brazil	A8	2020-04-22
KR102327096B1	Republic of Korea	B1	2021-11-16
CA2928009C	Canada	C	2022-08-30
BR112016011078B1	Brazil	B1	2022-12-06

5 legal events, as the office reported them to INPADOC

Point at a mark for the event

English: 1-(5-tert-butyl-2-aryl-pyrazol-3-yl)-3-[2-fluoro-4-[(3-oxo-4h-pyrido[2, 3-b]pyrazin-8-yl)oxy]phenyl]urea derivatives as raf inhibitors for the treatment of cancer
Hebrew: תולדות של 1–(5–טרט–בוטיל–2–אריל–פיראזול–3–איל)–3–[2–פלואורו–4–[(3–אוקסו–h4–פירידו[3,2–b]פיראזין–8–איל)אוקסי]פניל]אוריאה כמעכבי raf לטיפול בסרטן

CPC, 22: A61K31/4985
C07D471/04
A61K45/06
A61K2300/00
C07D401/14
C07D403/12
A61P1/00
A61P11/00
A61P11/02
A61P11/06
A61P17/00
A61P17/06
A61P27/04
A61P27/06
A61P27/16
A61P29/00
A61P31/12
A61P35/00
A61P35/02
A61P37/00
A61P43/00
A61P9/12
Filled: the office’s first classification

1-(5-tert-butyl-2-aryl-pyrazol-3-yl)-3-[2-fluoro-4-[(3-oxo-4h-pyrido[2, 3-b]pyrazin-8-yl)oxy]phenyl]urea derivatives as raf inhibitors for the treatment of cancer